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Abstract
Background: The way various antiretroviral drugs and drug combinations affect HIV-1 infection in the
central nervous system is still largely unknown. The aim of this study was to determine the cerebrospinal
fluid (CSF) steady-state concentrations of saquinavir and nelfinavir in relation to plasma concentrations,
and to study their effect in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) on
CSF viral loads, intrathecal immunoactivation, and blood-brain barrier integrity.
Methods: Paired CSF and plasma samples from 8 antiretroviral-naïve HIV-1 infected patients starting
combination therapy with saquinavir, nelfinavir, and two nucleoside analogues were collected prior to
treatment, and again after approximately 12 and 48 weeks of antiretroviral therapy. Additional plasma
samples were taken at weeks 2, 4, 8, 24, and 36. The concentrations of protease inhibitors were analysed,
as were levels of HIV-1 RNA, CD4+ T-cell count, β2-microglobulin, neopterin, albumin ratio, IgG index,
and monocytic cell count.
Results: None of the patients in the study presented with HIV-1 RNA < 50 copies/mL in CSF or plasma
prior to treatment, compared to 5/7 at the end of the study. Signs of cell-mediated intrathecal
immunoactivation, measured by neopterin and β2-microglobulin, decreased significantly in both CSF and
serum, although only 1/7 reached normal CSF neopterin levels after 48 weeks of treatment. There was no
significant reduction of albumin ratio, IgG index or CSF monocytic cell count. Saquinavir median (range)
concentrations were < 2.5 (< 2.5–96.0) nM unbound in plasma, and < 2.5 (< 2.5–9.0) nM total in CSF.
Nelfinavir median (range) concentrations were 10.0 (< 2.0–31.0) nM unbound in plasma, and < 2.0 (< 2.0–
23.0) nM total in CSF. Saquinavir and nelfinavir were detectable in 7/15 and 9/15 CSF samples, respectively.
Conclusion: Saquinavir and nelfinavir, in combination with two NRTIs, decrease the CSF viral load and,
to a lesser extent, intrathecal immunoactivation. We found reasonably high CSF concentrations of
nelfinavir, but suboptimal concentrations of saquinavir.
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Background
Antiretroviral combination therapy, where it is available,
has substantially decreased morbidity and mortality in
HIV-1 infection. Neurological complications and AIDS
dementia complex (ADC) are rarely seen nowadays in
patients on antiretroviral treatment. On the other hand,
neurological complications are common over the natural
course of HIV-1 infection as a result of infections,
tumours, and HIV-1 itself. Of the complications men-
tioned, ADC is the most feared, developing in about 15%
to 20% of all untreated HIV-1 infected patients [1,2].
HIV-1 can be found in the cerebrospinal fluid (CSF) in a
majority of HIV-1 infected individuals at all stages of the
disease, including primary infection [3]. It establishes an
active, productive infection early on, triggering an intrath-
ecal cell-mediated immune response that can be meas-
ured by elevated CSF concentrations of neopterin and β2-
microglobulin [4]. The HIV-1 infection also induces a
humoral immune response in the central nervous system
(CNS), as measured by an increased IgG index, in both
neurologically asymptomatic and symptomatic patients
[4-6]. In time, impairment of the blood-brain barrier
(BBB) function occurs, identified as a critical step in the
development of ADC [7-9].
It is well established that antiretroviral-naïve individuals
begun on highly active antiretroviral therapy (HAART)
will effectively reduce their viral loads, both in plasma and
CSF [10,11]. However, our knowledge of how various
antiretroviral drugs and drug combinations affect HIV-1
infection in the CNS is still limited.
Saquinavir was one of the first protease inhibitors (PIs)
registered for use in HIV-1 infected patients. It was ini-
tially introduced as saquinavir mesylate in a hard gelatin
capsule (hgc), and later as saquinavir free base in a soft
gelatin capsule (sgc) with improved bioavailability. The
co-administration of nelfinavir, another PI that is also
metabolized via the Cytochrome P450 (CYP) 3A enzyme,
results in an approximately five-fold increase in saquina-
vir plasma levels [12]. Saquinavir and nelfinavir in combi-
nation with two nucleoside reverse transcriptase
inhibitors (NRTIs) demonstrably cause a decrease in
plasma viral loads [13]. Today, PIs are almost exclusively
co-administered with low-dose ritonavir, a potent CYP
3A4 inhibitor. Neither saquinavir or nelfinavir has previ-
ously been reported to achieve detectable concentrations
in the CSF [14-16].
The M61022 study was an open monocentre pilot study
whose objective was to determine the steady-state concen-
trations of saquinavir and nelfinavir in CSF and plasma
when administered together, and to evaluate the impact
of these two PIs given in combination with two NRTIs on
CSF and plasma viral load. We additionally wanted to
determine their effect on cell-mediated and humoral
immune response, monocytic cell count, and BBB integ-
rity.
Methods
Patients
Eight antiretroviral-naïve HIV-1 infected patients were
recruited for the study after having given their informed
consent. One of the patients was diagnosed with ADC
stage 1 [17] and the other 7 were neurologically asympto-
matic. The study took place in Gothenburg, Sweden,
between July 1999 and June 2001, and was approved by
the Research Ethics Committee of Gothenburg University,
Sweden. The patients (four men and four women) were
between the ages of 27 and 59 (median age 39). Six origi-
nally came from Africa and two were Europeans. In 7
patients the HIV-1 infection had followed a heterosexual
route of transmission and in one it was homosexually
transmitted. Four patients were classified as asympto-
matic (CDC A) according to the Centers for Disease Con-
trol and Prevention (CDC) classification [18], three as
symptomatic (CDC B) due to molluscum contagiosum (n
= 1) and seborrheic dermatitis (n = 2), and one as AIDS
(CDC C) because of ADC.
All patients were treated with saquinavir-sgc 1200 mg BID
and nelfinavir 1250 mg BID; 7 were given a combination
of zidovudine and lamivudine; and one received zidovu-
dine and didanosine. The total plasma concentrations
were analysed five times in 6 patients, four times in one,
and three times in another, for a total of 37 samples. The
concentrations of the unbound PIs in plasma, and total
(bound and unbound) concentrations in CSF were ana-
lysed twice in 7 patients, and once in one, for a total of 15
samples. We were unable to measure the unbound CSF
concentrations of the PIs.
Methods
Lumbar punctures were performed at baseline, week 12,
and week 48. Plasma was also sampled at weeks 2, 4, 8,
24, and 36 for analysis of HIV-1 RNA. HIV-1 RNA was
quantified in cell-free plasma and CSF with quantitative
polymerase chain reaction (Amplicor, HIV-1 Monitor Test
version 1.5, Roche Diagnostic Systems, Hoffman-La
Roche, Basel, Switzerland) with a dynamic range down to
50 copies/mL (1.70 log10 copies/mL), and a detection
limit of approximately 20 copies/mL.
β2-microglobulin was measured by an enzyme-linked
immunosorbent assay [19]. Normal reference values were
≤ 2.4 mg/L in serum and ≤ 2.2 mg/L in CSF.
Neopterin was measured by a commercially available
radio-immunoassay [20] (Henningtest Neopterin,BMC Infectious Diseases 2006, 6:63 http://www.biomedcentral.com/1471-2334/6/63
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BRAHMS, Berlin, Germany). Normal reference values
were ≤ 8.8 nmol/L in serum and ≤ 4.3 nmol/L in CSF [21].
Quantitative determination of albumin and IgG in serum
and CSF was performed by nephelometry (Behring Neph-
elometer Analyzer, Behringwerke AG, Marburg, Ger-
many). To evaluate the BBB function, we used albumin
ratio, calculated as CSF albumin (mg/L)/serum albumin
(g/L). The reference values in the laboratory were < 6.8 for
individuals less than 45 years old and < 10.2 for individ-
uals over age 45 [22]. Intrathecal IgG production was
determined by the IgG index, calculated as [CSF IgG (mg/
L)/serum IgG (g/L)]/albumin ratio. The reference value
was < 0.63 [22].
The peripheral blood CD4+ T-cell count was measured by
direct immunofluorescence in a flow cytometer.
Sampling for analysis of concentrations after the last
intake of saquinavir and nelfinavir ranged from 0.25 to
13.25 hours (median 8.0). Saquinavir and nelfinavir were
determined by high pressure liquid chromatography
(HPLC), isocratic reversed phase, using an Ace 3 C18 3 µm
50 × 3.0 mm column from Scantec with UV-detection
(238 nm for saquinavir and 210 nm for nelfinavir). The
method for total plasma concentrations has been in use
for routine analysis for 10 years, is accredited, and is sub-
ject to external quality control programs. The samples are
worked up by protein precipitation upon adding 100 µL
acetonitrile to a 50 µL sample. After centrifugation the
supernatant is injected onto the HPLC column. The coef-
ficient of variation (CV) is less than 5% at 0.4 µM and 4.0
µM for saquinavir, and 1.6 µM and 16.0 µM for nelfinavir.
The levels of detection (LOD) were 0.08 µM and 0.13 µM,
respectively. Unbound plasma concentrations were deter-
Data from each patient (n = 8) displayed in paired graphs Figure 1
Data from each patient (n = 8) displayed in paired graphs. Upper panel indicates CSF and plasma viral load, and CD 4+ T-cell 
count. Lower panel shows concentrations of neopterin and β2-microglobulin in CSF and serum. Dotted line in upper panel 
indicates 50 (1.70 log10) HIV-1 RNA copies/mL. Time on X-axis in weeks.
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mined in ultrafiltrates using Amicon Centrifree cartridges
(Millipore) spun at 3000 rpm for 30 minutes at a temper-
ature of 37°C to obtain a total of 1 mL of filtrate. Methods
for analysis of total CSF and unbound plasma concentra-
tions were developed specifically for this study. One mL of
sample was extracted in a potassium-phosphate buffer of
pH 7.5 mixed with diphenyl-ether. After separation, the
organic phase was mixed with 75 µL of 100 mM phos-
phoric acid, and the aqueous phase was then separated
and mixed with 20 µL methanol. Thirty µL were injected
onto the column under the same conditions used for total
plasma concentrations. LOD were 2.5 nM and 2.0 nM for
saquinavir and nelfinavir, respectively. The methods were
linear (r > 0.99) over the concentration ranges studied.
Statistical analysis
Evaluation of paired pre- and on-treatment samples was
performed by Wilcoxon's signed rank test. Product-
moment correlation analysis was used to relate variables.
P < 0.05 was considered statistically significant.
Results
The effects of antiretroviral combination therapy with
saquinavir, nelfinavir, and two NRTIs on CSF and plasma
HIV-1 RNA, CSF and serum neopterin, CSF and serum β2-
microglobulin, CSF monocytic cell count, CD4+ T-cell
count, albumin ratio, and IgG index are shown in Figure
1 and Table 1.
The first follow-up with lumbar puncture took place at
median 12.5 weeks (range 12.0–19.0) and the second fol-
low-up at median 48.0 weeks (range 47.0–48.5). One
patient was withdrawn from the study at week 24 due to
treatment failure (patient 1). Another patient stopped tak-
ing all study drugs at week 36 and had a viral rebound at
week 48 (patient 4).
HIV-1 RNA decreased in both CSF and plasma after 12 (p
< 0.05) and 48 weeks (p < 0.05). After 12 weeks of treat-
ment, 6 out of 8 patients had CSF HIV-1 RNA, and 4 out
of 8 had plasma HIV-1 RNA < 50 copies/mL. After 48
Table 1: Effects of antiretroviral combination therapy with nelfinavir, saquinavir, and two nucleoside analogues upon CSF and plasma 
HIV-1 RNA, CSF and serum neopterin, CSF and serum β2-microglobulin (β2 m), CSF monocytic cell count, CD4+ T- cell count, 
albumin ratio, and IgG index.
Baseline Week 12 Week 48
CSF HIV-1 RNA (log10 copies/mL)
Median (range) 4.19 (2.20–5.40) 1.54 (1.28–2.27) 1.59 (1.28–3.10)
No. of patients < 1.70 log10 copies/mL 0/8 6/8 5/7
Plasma HIV-1 RNA (log10 copies/mL)
Median (range) 5.04 (3.85–5.58) 1.60 (1.28–2.50) 1.63 (1.28–5.29)
No. of patients < 1.70 log10 copies/mL 0/8 4/8 5/7
CSF neopterin (nmol/L)
Median (range) 25.5 (11.1–74.0) 10.7 (6.5–25.6) 7.0 (3.8–18.2)
No. of patients = 4.3 nmol/L 0/8 0/8 1/7
Serum neopterin (nmol/L)
Median (range) 16.4 (9.0–44.9) 10.1 (6.0–22.3) 7.0 (4.4–70.1)
No. of patients = 8.8 nmol/L 0/8 4/8 4/7
CSF β2 M (mg/L)
Median (range) 2.65 (1.10–7.10) 1.40 (0.70–3.10) 0.90 (0.50–1.60)
No. of patients = 2.2 mg/L 3/8 7/8 8/8
Serum β2 M (mg/L)
Median (range) 3.40 (1.70–4.50) 2.40 (1.40–3.30) 1.50 (1.30–4.30)
No. of patients = 2.4 mg/L 3/8 4/8 5/7
CSF monocytic cell count (x106/L)
Median (range) 11 (1–20) 1 (0–7) 1 (0–3)
No. of patients = 4 × 106 cells/L 3/7 7/8 7/7
CD4+ T-cell count (cells × 106/L)
Median (range) 200 (20–310) 305 (100–390) 330 (110–450)
No. of patients = 200 cells × 106/L 4/8 6/8 7/7
Albumin ratio
Median (range) 3.5 (2.1–10.8) 3.2 (2.1–11.8) 3.6 (1.8–3.8)
No. of patients with normal values 7/8 7/8 7/7
IgG index
Median (range) 0.98 (0.49–1.47) 0.88 (0.57–2.24) 0.70 (0.48–1.54)
No. of patients < 0.63 1/8 1/8 2/7BMC Infectious Diseases 2006, 6:63 http://www.biomedcentral.com/1471-2334/6/63
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weeks of treatment, 5 out of 7 patients had HIV-1 RNA <
50 copies/mL in both CSF and plasma.
The levels of neopterin and β2-microglobulin also
decreased in both CSF and plasma (p < 0.05). Before ther-
apy, 3 out of 8 patients had normal levels of β2-
microglobulin in CSF and serum, but neopterin in all of
the patients was above the reference value.
No statistically significant reduction of IgG index was
found during treatment. Only one patient had a normal
IgG index at baseline, and 2 out of 7 had normal IgG indi-
ces at the end of the study. Albumin ratio at baseline was
normal in all but one patient.
Saquinavir and nelfinavir median (range) concentrations
in plasma and CSF are shown in Table 2. Saquinavir and
nelfinavir were detectable in 7 out of 15, and 9 out of 15
CSF samples, respectively. A high degree of protein bind-
ing in plasma was found: 97.7 ± 0.80% for saquinavir and
99.7 ± 0.10% for nelfinavir. The detectable total CSF and
unbound plasma concentrations of nelfinavir and
saquinavir depend on the time after last intake of the
antiretroviral drugs, as shown in Figure 2.
Discussion
The combination of saquinavir plus nelfinavir is not used
in HIV-treatment regimens today, mainly due to the high
pill burden and side effects. It is, however, of importance
to understand the effects and penetration abilities of vari-
ous drugs into different compartments of the body. This
study hopes to contribute to the literature available on the
impact of antiretroviral drugs on CNS HIV-1 infection. A
combination of saquinavir, nelfinavir, and two NRTIs
effectively reduces CSF and plasma viral loads in antiret-
roviral-naïve HIV-1 infected individuals. The CSF
saquinavir concentrations we found were suboptimal and
did not exceed the 50% inhibitory concentration (IC50)
for wild-type virus [23]. It has been shown earlier that
ritonavir-boosted saquinavir alone, without NRTIs,
decreases viral load less in CSF than in plasma [24]. How-
ever, in contrast to previous studies [15,25], we found
detectable and, in most cases, reasonably high CSF nelfi-
navir concentrations in the range of the IC50 [23]. One
explanation for this could be the lower limit of detection
in our study. The total CSF levels of nelfinavir were of the
same magnitude as the unbound levels in plasma, but it
cannot be determined from our study whether the CSF
concentrations were sufficient to exert an adequate
antiretroviral effect. The reduction of viral load to unde-
tectable levels in the CSF, despite suboptimal penetration
of the PIs, may occur because such reduction is easier in
CSF than in plasma. Even before the introduction of PIs,
patients treated with only one or two NRTIs more com-
monly achieved viral loads below the detection limit in
CSF than they did in plasma [26]. It should be noted that
the pharmacologically-active metabolite of nelfinavir
called M8 was not analysed in this study.
We were unable to measure the unbound CSF concentra-
tions of saquinavir and nelfinavir. A risk of overestimating
CSF exposure to the PIs exists if the degree of protein bind-
ing in the CSF is not taken into account. The fraction of
unbound and active drug in the CSF is probably substan-
tially smaller than the total CSF concentration, due to a
measurable amount of protein binding capacity in the
CSF. For efavirenz, protein binding in the CSF to a signif-
icant degree has been shown (L. Moberg, L. Ståhle, and A.
Sönnerborg, unpublished data).
With the exception of indinavir [27], all other PIs, includ-
ing saquinavir and nelfinavir, are highly bound to albu-
min and α-1 acid glycoprotein in plasma. It is the small,
unbound, and pharmacologically-active fraction that pen-
etrates the BBB to distribute itself within the brain. In
addition to the high degree of protein binding, both
saquinavir and nelfinavir are substrates of P-glycoprotein,
an efflux membrane transporter, situated in the BBB and
preventing the entry of certain drugs into the CNS [28].
The PIs are lipophilic compounds with high molecular
weight that further restricts their penetration into the CSF.
Among the other PIs, indinavir, especially ritonavir-
boosted, reaches CSF concentrations that exceed the IC50
[29]. Lopinavir reaches low but detectable levels in the
CSF that are probably sufficient to have a virological effect
[30,31].
An important issue awaiting more extensvie study is the
degree to which drug concentrations in the CSF reflect
drug levels reached within the brain parenchyma. The
antifungal drug amphotericin, for example, achieves good
penetration in the brain without detectable concentra-
Table 2: Saquinavir and nelfinavir median (range) concentrations in plasma and CSF.
Plasma CSF
total (µM) unbound (nM) total (nM)
Saquinavir 0.3 (< 0.08–6.6) < 2.5 (< 2.5–96.0) < 2.5 (< 2.5–9.0)
Nelfinavir 4.1 (< 0.13–10.6) 10.0 (< 2.0–31.0) < 2.0 (< 2.0–23.0)BMC Infectious Diseases 2006, 6:63 http://www.biomedcentral.com/1471-2334/6/63
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tions in the CSF [32]. Measurements of CSF concentra-
tions of HIV drugs should be interpreted with caution
until they are better understood, as CSF levels are not nec-
essarily useful for extrapolating concentrations within the
brain [33].
HIV-1 infection in the CNS triggers an intrathecal
immune response both in individuals with or without
neurological complications [4]. The cell-mediated part of
this immune response can be measured as increased levels
of neopterin and β2-microglobulin. The highest levels of
CSF neopterin are found in HIV-1 infected patients with
opportunistic CNS infections or ADC, but moderately
increased levels are frequently found in asymptomatic
HIV-1 infected individuals [34]. Neopterin and β2-
microglobulin have earlier been shown to decrease signif-
icantly in CSF during HAART, although 45% of such
patients still have slightly elevated neopterin levels after
two years of treatment [35]. This is in contrast to the suc-
cessful antibiotic therapy of Lyme neuroborreliosis, where
CSF neopterin levels drop rather rapidly [36]. In the
present study, only 1 out of 7 patients had a normal CSF
neopterin level at the end of the study, indicating a persist-
ent, low-grade, intrathecal, cell-mediated immunoactiva-
tion. This immunoactivation might reflect an ongoing
low degree of viral replication, incapable of detection by
current HIV-1 RNA quantification assays. Consequently,
CSF neopterin might be preferable to CSF HIV-1 RNA
quantification for evaluating HIV-1 brain infection in
neuroasymptomatic individuals, although the impor-
tance or possible harm of elevated levels of HIV-1 RNA
and/or neopterin in CSF is not fully established. High CSF
neopterin levels during treatment might also be due to
intrathecal immunoactivation reflecting an unspecific
reaction to HIV-1 infection, and a slower down-regulation
of the immunoactivation taking place in the CNS than in
the periphery.
Intrathecal immunoglobulin production is prevalent at all
stages of HIV-1 infection, but is most frequently found in
the early asymptomatic stages [4-6]. This humoral immu-
noactivation seems to be persistent, despite otherwise
effective antiretroviral treatment [37], a finding that has
been confirmed in our study, where the vast majority of
patients still had an elevated IgG index after 48 weeks of
treatment.
As others have noted, CSF monocytic cell count normal-
ised during HAART [38,39], even though the decrease was
not statistically significant.
The BBB serves as an important protective mechanism for
the brain by preventing potentially harmful substances
entering the CNS from the blood. The major difference
between capillaries in general and capillaries in the brain
is that the latter possess tight junctions, although other
factors also contribute to the properties of the BBB.
Impaired BBB function is a common finding in the later
stages of HIV-1 infection, and there is a strong correlation
between neurological symptoms and increased BBB per-
meability [6,7]. The only patient in our study who had an
elevated albumin ratio prior to and during treatment was
an individual with ADC. Altered BBB function may play a
role in the pathogenesis of ADC by facilitating the entry of
Plasma unbound and CSF total concentrations as a function of time since last intake of antiretroviral drugs: (a) saquinavir, (b)  nelfinavir Figure 2
Plasma unbound and CSF total concentrations as a function of time since last intake of antiretroviral drugs: (a) saquinavir, (b) 
nelfinavir.
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virus or serum products [8]. Perivascular inflammation,
monocyte infiltration [9], and leakage of serum proteins
into the brain (appearing as diffuse white matter enhance-
ment in magnetic resonance imaging) may also be signif-
icant elements.
Conclusion
A combination of saquinavir, nelfinavir, and two NRTIs
effectively reduces the CSF and plasma viral loads in
antiretroviral-naïve HIV-1 infected individuals. We deter-
mined that there were suboptimal concentrations of
saquinavir in CSF. Contrary to earlier studies, we found
detectable and reasonably high CSF nelfinavir concentra-
tions in a majority of patients.
Competing interests
UN is employed by Roche AB, the manufacturer of
saquinavir and nelfinavir. The other authors declare that
they have no competing interests.
Authors' contributions
AY, LH, UN, and MG contributed to the conception of the
study, data interpretation, and the writing of the paper.
DF performed the neopterin analysis and assisted in draft-
ing the manuscript. LS and JOS performed the analysis
and interpretation of the concentrations of saquinavir and
nelfinavir, and helped in drafting the manuscript.
Acknowledgements
This study was supported by grants from the National Institutes of Health 
(NINDS R01 NS43103-01), the Medical Faculty of Göteborg University 
(ALFGBG-2874), the Göteborg Medical Society, the Research Foundation 
of Swedish Physicians Against AIDS, Roche AB, and the government of the 
State of the Austrian Tyrol.
References
1. Portegies P, Enting RH, de Gans J, Algra PR, Derix MM, Lange JM,
Goudsmit J: Presentation and course of AIDS dementia com-
plex: 10 years of follow-up in Amsterdam, The Netherlands.
Aids 1993, 7:669-675.
2. Brew BJ, Pemberton L, Cunningham P, Law MG: Levels of human
immunodeficiency virus type 1 RNA in cerebrospinal fluid
correlate with AIDS dementia stage.  J Infect Dis 1997,
175:963-966.
3. Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlen M, Fenyo
EM, Norkrans G: Human immunodeficiency virus type 1 is
present in the cerebrospinal fluid of a majority of infected
individuals.  J Clin Microbiol 1992, 30:1768-1771.
4. Gisslén M, Chiodi F, Fuchs D, Norkrans G, Svennerholm B, Wachter
H, Hagberg L: Markers of immune stimulation in the cerebro-
spinal fluid during HIV infection: a longitudinal study.  Scand J
Infect Dis 1994, 26:523-533.
5. Hagberg L, Forsman A, Norkrans G, Rybo E, Svennerholm L: Cyto-
logical and immunoglobulin findings in cerebrospinal fluid of
symptomatic and asymptomatic human immunodeficiency
virus (HIV) seropositive patients.  Infection 1988, 16:13-18.
6. Marshall DW, Brey RL, Cahill WT, Houk RW, Zajac RA, Boswell RN:
Spectrum of cerebrospinal fluid findings in various stages of
human immunodeficiency virus infection.  Arch Neurol 1988,
45:954-958.
7. Marshall DW, Brey RL, Butzin CA, Lucey DR, Abbadessa SM, Boswell
RN: CSF changes in a longitudinal study of 124 neurologically
normal HIV-1-infected U.S. Air Force personnel.  J Acquir
Immune Defic Syndr 1991, 4:777-781.
8. Power C, Kong PA, Crawford TO, Wesselingh S, Glass JD, McArthur
JC, Trapp BD: Cerebral white matter changes in acquired
immunodeficiency syndrome dementia: alterations of the
blood-brain barrier.  Ann Neurol 1993, 34:339-350.
9. Boven LA, Middel J, Verhoef J, De Groot CJA, Nottet HSLM: Mono-
cyte infiltration is highly associated with loss of the tight
junction protein zonula occludens in HIV-1-associated
dementia.  Neuropathol Appl Neurobiol 2000, 26:356-360.
10. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White ACJ,
Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A,
Japour A, Sun E: ABT-378/ritonavir plus stavudine and lamivu-
dine for the treatment of antiretroviral-naive adults with
HIV-1 infection: 48-week results.  Aids 2001, 15:F1-9.
11. Gisslén M, Norkrans G, Svennerholm B, Hagberg L: HIV-1 RNA
detectable with ultrasensitive quantitative polymerase chain
reaction in plasma but not in cerebrospinal fluid during com-
bination treatment with zidovudine, lamivudine and indina-
vir.  Aids 1998, 12:114-116.
12. Merry C, Barry MG, Mulcahy F, Halifax KL, Back DJ: Saquinavir
pharmacokinetics alone and in combination with nelfinavir
in HIV-infected patients.  Aids 1997, 11:F117-20.
13. Moyle G, Pozniak A, Opravil M, Clumeck N, DelFraissy JF, Johnson M,
Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M, Duff F: The
SPICE study: 48-week activity of combinations of saquinavir
soft gelatin and nelfinavir with and without nucleoside ana-
logues. Study of Protease Inhibitor Combinations in Europe.
J Acquir Immune Defic Syndr 2000, 23:128-137.
14. Kravcik S, Gallicano K, Roth V, Cassol S, Hawley-Foss N, Badley A,
Cameron DW: Cerebrospinal fluid HIV RNA and drug levels
with combination ritonavir and saquinavir.  J Acquir Immune
Defic Syndr 1999, 21:371-375.
15. Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P,
Novakovic-Agopian T, Price RW: Failure to detect nelfinavir in
the cerebrospinal fluid of HIV-1-infected patients with and
without AIDS dementia complex.  J Acquir Immune Defic Syndr
Hum Retrovirol 1999, 20:39-43.
16. Moyle GJ, Sadler M, Buss N: Plasma and cerebrospinal fluid
saquinavir concentrations in patients receiving combination
antiretroviral therapy.  Clin Infect Dis 1999, 28:403-404.
17. Price RW, Brew BJ: The AIDS dementia complex.  J Infect Dis
1988, 158:1079-1083.
18. 1993 revised classification system for HIV infection and
expanded surveillance case definition for AIDS among ado-
lescents and adults.  MMWR Morb Mortal Weekly Rep 1992,
41:RR-17.
19. Bjerrum OW, Lage S, Hansen OE: Measurement of beta-2-
microglobulin in human cerebrospinal fluid by ELISA tech-
nique.  Acta Neurol Scand 1986, 74:177-180.
20. Werner E, Bichler A, Daxenbichler G, Fuchs D, Fuith L, Hausen A:
Determination of neopterin in serum and urine.  Clin Chem
1987, 33:62-66.
21. Hagberg L, Andersson LM, Abdulle S, Gisslén M: Clinical Applica-
tion of Cerebrospinal Fluid Neopterin Concentrations in
HIV infection.  Pteridines 2004, 15:102-106.
22. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Lang-
strom G, Skoog I, Svennerholm L, Wikkelso C: Protein analysis in
cerebrospinal fluid. II. Reference values derived from healthy
individuals 18-88 years of age.  Eur Neurol 1993, 33:129-133.
23. Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, Grabowski
B, Denissen JF, Kohlbrenner W, Plattner JJ, Leonard JM, Norbeck
DW, Kempf DJ: Human serum attenuates the activity of pro-
tease inhibitors toward wild-type and mutant human immu-
nodeficiency virus.  Virology 1998, 250:255-262.
24. Gisolf EH, Enting  RH, Jurriaans S, de Wolf F,  van der Ende ME,
Hoetelmans RM, Portegies P, Danner  SA: Cerebrospinal fluid
HIV-1 RNA during treatment with ritonavir/saquinavir or
ritonavir/saquinavir/stavudine.  Aids 2000, 14:1583-1589.
25. Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans
RM, Piscitelli SC: Efficacy of cerebrospinal fluid (CSF)-pene-
trating antiretroviral drugs against HIV in the neurological
compartment: different patterns of phenotypic resistance in
CSF and plasma.  Clin Infect Dis 2005, 41:1787-1793.
26. Gisslén M, Svennerholm B, Norkrans G, Franzen C, Sall C, Svensson
R, Öberg S, Hagberg L: Cerebrospinal fluid and plasma viral
load in HIV-1-infected patients with various anti-retroviral
treatment regimens.  Scand J Infect Dis 2000, 32:365-369.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2006, 6:63 http://www.biomedcentral.com/1471-2334/6/63
Page 8 of 8
(page number not for citation purposes)
27. Ståhle L, Martin C, Svensson JO, Sönnerborg A: Indinavir in cere-
brospinal fluid of HIV-1-infected patients.  Lancet 1997,
350:1823.
28. Thomas SA: Anti-HIV drug distribution to the central nervous
system.  Curr Pharm Des 2004, 10:1313-1324.
29. Martin C, Sönnerborg A, Svensson JO, Ståhle L: Indinavir-based
treatment of HIV-1 infected patients: efficacy in the central
nervous system.  Aids 1999, 13:1227-1232.
30. Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M:
Cerebrospinal fluid and plasma HIV-1 RNA levels and lopina-
vir concentrations following lopinavir/ritonavir regimen.
Scand J Infect Dis 2004, 36:823-828.
31. Capparelli EV, Holland D, Okamoto C, Gragg B, Durelle J, Marquie-
Beck J, van den Brande G, Ellis R, Letendre S: Lopinavir concentra-
tions in cerebrospinal fluid exceed the 50% inhibitory con-
centration for HIV.  Aids 2005, 19:949-952.
32. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS,
Piscitelli SC, Walsh TJ: Comparative efficacy and distribution of
lipid formulations of amphotericin B in experimental Cand-
ida albicans infection of the central nervous system.  J Infect
Dis 2000, 182:274-282.
33. Groothuis DR, Levy RM: The entry of antiviral and antiretrovi-
ral drugs into the central nervous system.  J Neurovirol 1997,
3:387-400.
34. Gisslén M, Fuchs D, Svennerholm B, Hagberg L: Cerebrospinal fluid
viral load, intrathecal immunoactivation, and cerebrospinal
fluid monocytic cell count in HIV-1 infection.  J Acquir Immune
Defic Syndr 1999, 21:271-276.
35. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M: Continu-
ing intrathecal immunoactivation despite two years of effec-
tive antiretroviral therapy against HIV-1 infection.  Aids 2002,
16:2145-2149.
36. Dotevall L, Fuchs D, Reibnegger G, Wachter H, Hagberg L: Cerebro-
spinal fluid and serum neopterin levels in patients with Lyme
neuroborreliosis.  Infection 1990, 18:210-214.
37. Abdulle S, Hagberg L, Gisslén M: Effects of antiretroviral treat-
ment on blood-brain barrier integrity and intrathecal immu-
noglobulin production in neuroasymptomatic HIV-1-
infected patients.  HIV Med 2005, 6:164-169.
38. Cinque P, Bestetti A, Marenzi R, Sala S, Gisslén M, Hagberg L, Price
RW: Cerebrospinal fluid interferon-gamma-inducible protein
10 (IP-10, CXCL10) in HIV-1 infection.  J Neuroimmunol 2005,
168:154-163.
39. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks
SG, Paxinos EE, Price RW: Cerebrospinal fluid HIV infection and
pleocytosis: Relation to systemic infection and antiretroviral
treatment.  BMC Infect Dis 2005, 5:98.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/6/63/prepub